MOTS-c

When your cells make energy, the tiny structures responsible (mitochondria) don't just produce fuel — they also send out chemical signals. MOTS-c is one of those signals. It's a very small protein, only 16 amino acids long, that travels from your mitochondria to your cell's nucleus and into your bloodstream. Researchers are interested in it because it seems to improve the way the body handles blood sugar, may protect muscles as you age, and rises in the blood after exercise — which is why some have called it an "exercise mimetic." The hype outpaces the evidence. Most of what we know comes from mouse studies. Human data confirms that circulating MOTS-c levels are lower in people with type 2 diabetes and decline with age, but no completed clinical trial has yet tested whether injecting native MOTS-c into people produces the metabolic benefits seen in mice. The one human-proximate Phase 1 trial (n=20) tested a modified analog called CB4211, not native MOTS-c, and did not meet its primary liver-fat efficacy endpoint.

MOTS-c is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded by a short open reading frame nested within the MT-RNR1 (12S rRNA) gene of the mitochondrial genome — a rare example of a mitochondrially-encoded bioactive peptide. Upon synthesis in mitochondria, MOTS-c translocates to the nucleus under metabolic stress, where it modulates nuclear gene expression (particularly genes involved in glucose metabolism and proteostasis), representing a retrograde mitochondria-to-nucleus signaling axis. Its primary characterised metabolic mechanism involves inhibition of the folate cycle and de novo purine biosynthesis in skeletal muscle, leading to intracellular accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), a known endogenous AMPK activator — AMPK activation then drives glucose uptake, fatty acid oxidation, and mitochondrial biogenesis while suppressing gluconeogenesis. Human serum MOTS-c levels are inversely correlated with age and with metabolic disease markers (best established in T2DM via a 2024 meta-analysis, n=602). An Asian-specific mitochondrial variant m.1382A>C (rs111033358) produces a K14Q substitution in MOTS-c associated with increased T2DM prevalence in males in a meta-analysis of approximately 27,500 subjects — a sex-dimorphic genetic association with meaningful implications for interpreting baseline MOTS-c biology across populations. CRITICAL: interventional evidence in humans is essentially absent. The one Phase 1a/1b trial in the MOTS-c literature (NCT03998514, n=20) tested CB4211 — a modified analog developed by CohBar Inc. (the commercial entity founded by the research network that discovered MOTS-c) — not the native peptide, and did not meet its primary MRI-PDFF liver-fat efficacy endpoint.

• NO PUBLISHED FORMAL HUMAN SAFETY DATA FOR NATIVE MOTS-C. FDA has explicitly noted the absence of human exposure data for compounded MOTS-c by any route.
• Injection-site reactions (in CB4211 ANALOG trial; ~20% of participants in some accounts; led to mid-trial protocol amendment for injection technique). NOT data for native MOTS-c.
• No serious adverse events reported in the CB4211 n=11 treated arm over 28 days.
• No clinically significant laboratory abnormalities (hepatic, renal, hematologic) reported in the CB4211 analog trial.
• Anecdotal online-forum reports (NOT controlled clinical data) include injection-site reactions, transient fatigue, and palpitations; should be weighted accordingly.

• Active malignancy (immunogenicity + pro-metabolic signaling uncertainty; theoretical, mechanism-based)
• Pregnancy and lactation (no safety data in any species)
• Concurrent AMPK-activating medications (metformin, AICAR, other activators) without glucose monitoring — theoretical additive hypoglycemia
• Known hypersensitivity to MOTS-c or any excipient in a specific compounded preparation
• Due to complete absence of published human safety data for native MOTS-c, all populations should be considered contraindicated for clinical use outside formal research settings.

• No published drug-interaction data in humans.
• Metformin — both activate AMPK; combined use theoretically additive. Glucose monitoring warranted.
• Insulin and GLP-1 agonists — theoretical additive hypoglycemia risk via MOTS-c insulin-sensitizing effect.
• Other AMPK activators (AICAR, BAM15) — class-level additive concern.
• Corticosteroids — theoretical attenuation of metabolic effects; not formally studied.

MOTS-c is unusual because it is encoded by mitochondrial DNA — the small, separate genome inside the cell's energy-producing structures. Almost all other peptides and proteins in the body are encoded by nuclear DNA. It was discovered in 2015 when researchers found a tiny protein-coding sequence hidden inside a gene previously thought to only code for structural RNA. This mitochondrial origin is why some researchers view it as part of a mitochondria-to-nucleus communication system and why it is classified as a mitochondrial-derived peptide (MDP). Its biology is genuinely novel; the hype around it, however, far outpaces the available clinical evidence.

Partially, and with important caveats. In humans, circulating MOTS-c rises after acute exercise and is higher in athletes vs sedentary individuals — suggesting it participates in the body's response to exercise. In mice, injecting MOTS-c doubled running capacity and restored function in aged animals. However, the leap from "this peptide goes up when you exercise" to "injecting it will mimic exercise" is not validated in humans. "Exercise mimetic" is academic-research framing of the research direction, not a description of a proven clinical effect. No human trial has tested whether exogenous MOTS-c injection produces measurable improvements in physical performance equivalent to exercise.

No. MOTS-c is explicitly named on the 2026 WADA Prohibited List under S4.4.1 (AMPK Activators), prohibited in-competition AND out-of-competition in all sports. Any athlete subject to anti-doping rules — including under USADA, UKAD, ASADA, or any WADA-code signatory — risks a violation and potential multi-year ban. This is not a grey area.

Not exactly. In April 2026, the FDA removed MOTS-c from its 503A Category 2 list — but this happened because the party that originally nominated it for review withdrew their nomination, not because the FDA cleared it as safe or effective. MOTS-c is still NOT on the 503A Bulk Drug Substances approved list (Category 1), meaning it is not currently authorized for compounding. The FDA has scheduled a formal Pharmacy Compounding Advisory Committee review for July 23–24, 2026 (docket FDA-2025-N-6895) to evaluate whether it should be added to the approved list for obesity and osteoporosis. That review has not happened yet. Regulatory status is in motion, but MOTS-c does not have FDA approval and is not currently authorized for compounding.

CB4211 is a MODIFIED ANALOG of MOTS-c developed by CohBar Inc. — a biotechnology company co-founded by Pinchas Cohen, one of the original MOTS-c discoverers. CB4211 was engineered to be more chemically stable and have improved pharmacokinetics compared to native MOTS-c. It completed a Phase 1a/1b clinical trial in 20 obese patients with liver fat (NCT03998514), showing safety/tolerability and modest liver-enzyme reductions — but no significant reduction in liver fat vs placebo (−5.03% CB4211 vs −4.88% placebo). CB4211 is NOT the same molecule as native MOTS-c, and results cannot be directly extrapolated. As of April 2026, no further CB4211 clinical trials have been publicly announced.

In mice, yes — with robust effects in diet-induced and genetic obesity models. In humans, the honest answer is: we don't know yet. Observational human data shows that people with type 2 diabetes and obesity have lower circulating MOTS-c levels (2024 meta-analysis, n=602). But lower endogenous levels and benefit from exogenous supplementation are different questions. The only interventional human-proximate trial (CB4211 analog, n=11) showed enzyme improvements but NO significant liver-fat reduction vs placebo. No completed human trial has tested native MOTS-c for weight loss.

The honest answer is: unknown. There are NO published human safety pharmacology studies for native MOTS-c. The CB4211 ANALOG showed short-term tolerability in 11 patients over 28 days — that is not native-peptide safety data. The FDA has explicitly stated there is no human exposure data for compounded MOTS-c by any route. Theoretical safety concerns include immunogenicity, supraphysiologic AMPK activation effects, and potential hypoglycemia in combination with antidiabetic drugs. Anyone using MOTS-c outside a clinical-trial context is doing so without the benefit of formal safety characterization for the specific compound being administered.

Five items, separately reported. (1) LC-MS confirmation of the expected [M+H]⁺ ~2,175.6 Da (monoisotopic or average — specify which). Any significant peak at +16 or +32 Da indicates methionine oxidation, the primary MOTS-c degradation marker — oxidized MOTS-c may have reduced bioactivity. (2) Explicit SALT-FORM declaration — free base, acetate, or TFA — and separate peptide-content percentage (not just HPLC chromatographic purity). The FDA evaluates free-base and acetate as distinct substances. (3) CHIRAL or orthogonal MS confirmation that Trp³ and the two Tyr residues have not racemized during synthesis — standard RP-HPLC cannot detect this. (4) MW cross-check against the expected ~2,174.6 Da free acid — substantial deviation without salt-form justification is a red flag. (5) Endotoxin testing per USP <85> for an injectable product. A COA showing only '≥98% purity by HPLC' without these items has not characterized what is actually in the vial.

MOTS-c was discovered in 2015 — about 11 years old as a research target. The preclinical literature is reasonably developed, with strong mechanistic work in mouse models and growing human OBSERVATIONAL data (2024 meta-analysis n=602 is the highest-quality). What is genuinely missing: any completed interventional RCT of native MOTS-c in humans for any indication; published human pharmacokinetic data; long-term safety data of any kind; and independent replication free from the USC / CohBar commercial conflict of interest, since most foundational research originates there. The July 2026 FDA PCAC review may meaningfully change the landscape, but as of April 22, 2026 the native-peptide interventional evidence is absent.